# EDGAR Filing Document

**Accession Number:** 0001666178
**File Stem:** 0001640334-23-000452
**Filing Date:** 2023-3
**Character Count:** 51599
**Document Hash:** 91f09bf545d5973f5f1383afc3209304
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001640334-23-000452.hdr.sgml**: 20230327

**ACCESSION NUMBER**: 0001640334-23-000452

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 38

**CONFORMED PERIOD OF REPORT**: 20210930

**FILED AS OF DATE**: 20230327

**DATE AS OF CHANGE**: 20230327

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lazuriton Nano Biotechnology (U.S.A.) Inc.
- **CENTRAL INDEX KEY:** 0001666178
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190]
- **IRS NUMBER:** 371786808
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-210091
- **FILM NUMBER:** 23765220

**BUSINESS ADDRESS:**
- **STREET 1:** 10F., NO.341, SEC.2, WANSHOU RD.
- **STREET 2:** GUISHAN DIST.
- **CITY:** TAOYUAN CITY
- **STATE:** F5
- **ZIP:** 333
- **BUSINESS PHONE:** 88633295585

**MAIL ADDRESS:**
- **STREET 1:** 10F., NO.341, SEC.2, WANSHOU RD.
- **STREET 2:** GUISHAN DIST.
- **CITY:** TAOYUAN CITY
- **STATE:** F5
- **ZIP:** 333

?xml version="1.0" encoding="utf-8"?lznn_10q.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 10-Q**

**(Mark One)**

---

| | |
|:---|:---|
| ☒ | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|  | FOR THE QUARTERLY PERIOD ENDED **September 30, 2021** |
| ☐ | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT  |
|  | FOR THE TRANSITION PERIOD FROM _____________ TO _____________ |

---

**COMMISSION FILE NUMBER 333-210091**

---

| |
|:---|
| **Lazuriton Nano Biotechnology (U.S.A.) Inc.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Nevada** | **37-1786808** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |

---

**341, Sec. 2, Wanshou Road, 10th Floor**

**<u>Guishan District, Taoyuan City, 333, Taiwan (Republic of China)</u>**

(Address of principal executive offices, Zip Code)

**<u>011-886-3-329-5585</u>**

(Registrant's telephone number, including area code)

____________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐&nbsp;&nbsp;&nbsp;&nbsp; No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such fi les). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non- accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated Filer | ☐ | Smaller reporting company | ☒ |
| (Do not check if a smaller reporting company) | (Do not check if a smaller reporting company) | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A | N/A |

---

The number of shares of registrant's common stock outstanding, as of March 9, 2023 was 100,000,000.

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| [Item 1.](#P1I1) | [Financial Statements](#P1I1) | 3 |
| [Item 2.](#P1I2) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#P1I2) | 11 |
| [Item 3.](#P1I3) | [Quantitative and Qualitative Disclosures About Market Risk](#P1I3) | 13 |
| [Item 4.](#P1I4) | [Controls and Procedures](#P1I4) | 13 |
|  | [PART II - OTHER INFORMATION](#P2) |  |
| [Item 1.](#P2I1) | [Legal Proceedings](#P2I1) | 14 |
| [Item 2.](#P2I2) | [Unregistered Sales of Equity Securities and Use of Proceeds](#P2I2) | 14 |
| [Item 3.](#P2I3) | [Defaults Upon Senior Securities](#P2I3) | 14 |
| [Item 4.](#P2I4) | [Mine Safety Disclosures](#P2I4) | 14 |
| [Item 5.](#P2I5) | [Other Information](#P2I5) | 14 |
| [Item 6.](#P2I6) | [Exhibits](#P2I6) | 15 |
| [SIGNATURES](#SIG) | [SIGNATURES](#SIG) | 16 |

---

---

| |
|:---|
| 2 |
| *[**Table of Contents**](#TOC)* |

---

**PART I - FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC. AND SUBSIDIARY**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **September 30, 2021** | **December 31, 2020** |
|  | **(Unaudited)** | |
| **Assets** | **Assets** | **Assets** |
| Current Assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $1348 | $1348 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1348 | 1348 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Assets** | $1348 | $1348 |
| **Liabilities and Stockholders' Deficit** | **Liabilities and Stockholders' Deficit** | **Liabilities and Stockholders' Deficit** |
| Current Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | $102547 | $77697 |
| &nbsp;&nbsp;&nbsp;&nbsp;Due to related parties | 249428 | 243428 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 351975 | 321125 |
| Total Liabilities | 351975 | 321125 |
| Stockholders' Deficit |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.0001 par value; 750,000,000 shares authorized, 100,000,000 shares issued and outstanding | 10000 | 10000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 250000 | 250000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (610627) | (579777) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' deficit | (350627) | (319777) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Liabilities and Stockholders' Deficit** | $1348 | $1348 |

---

The accompanying notes to financial statements are an integral part of these statements.

---

| |
|:---|
| 3 |
| *[**Table of Contents**](#TOC)* |

---

**LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC. AND SUBSIDIARY**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(UNAUDITED)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** <br>**September 30,** | **For the Three Months Ended** <br>**September 30,** | **For the Nine Months Ended** <br>**September 30,** | **For the Nine Months Ended** <br>**September 30,** |
|  | **2021** | **2020** | **2021** | **2020** |
| Net revenue | $- | $- | $- | $- |
| General and administrative expenses | 9950 | 10818 | 30850 | 32292 |
| Loss from operations | (9950) | (10818) | (30850) | (32292) |
| Other income |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | - | - | - | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income | - | - | - | 1 |
| Loss before income taxes | (9950) | (10818) | (30850) | (32291) |
| Provision for income taxes  | - | - | - | - |
| Net loss | $(9950) | $(10818) | $(30850) | $(32291) |
| Net loss per share  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | $(0.00) | $(0.00) | $(0.00) | $(0.00) |
| Weighted Average Shares Outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | 100000000 | 100000000 | 100000000 | 100000000 |

---

The accompanying notes to financial statements are an integral part of these statements.

---

| |
|:---|
| 4 |
| *[**Table of Contents**](#TOC)* |

---

**LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC. AND SUBSIDIARY**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **For the Nine Months Ended**<br>**September 30,** | **For the Nine Months Ended**<br>**September 30,** |
|  | **2021** | **2020** |
| Cash Flows from Operating Activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(30850) | $(32291) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase in accrued expenses | 24850 | 22152 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase in due to related parties | 6000 | 10140 |
| **Net cash provided by operating activities** | **-** | 1 |
| **Net increase in cash and cash equivalents** |  | 1 |
| Cash and Cash Equivalents |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Beginning | 1348 | 1347 |
| &nbsp;&nbsp;&nbsp;&nbsp;Ending | $1348 | $1348 |
| Supplemental Disclosure of Cash Flows |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid during the year for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expenses | $- | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes | $- | $- |

---

The accompanying notes to financial statements are an integral part of these statements.

---

| |
|:---|
| 5 |
| *[**Table of Contents**](#TOC)* |

---

**LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC. AND SUBSIDIARY**

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT**

**(UNAUDITED)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** | <br>**Accumulated**<br>**Deficit** | <br><br>**Total** |
| Balance at December 31, 2020 | 100000000 | $10000 | $250000 | $(579777) | $(319777) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | - | - | - | (10950) | (10950) |
| Balance at March 31, 2021 | 100000000 | 10000 | 250000 | (590727) | (330727) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | - | - | - | (9950) | (9950) |
| Balance at June 30, 2021 | 100000000 | 10000 | 250000 | (600677) | (340677) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | - | - | - | (9950) | (9950) |
| Balance at September 30, 2021 | 100000000 | $10000 | $250000 | $(610627) | $(350627) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** | <br>**Accumulated**<br>**Deficit** | <br><br>**Total** |
| Balance at December 31, 2019 | 100000000 | $10000 | $250000 | $(528536) | $(268536) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | - | - | - | (11450) | (11450) |
| Balance at March 31, 2020 | 100000000 | 10000 | 250000 | (539986) | (279986) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | - | - | - | (10023) | (10023) |
| Balance at June 30, 2020 | 100000000 | 10000 | 250000 | (550009) | (290009) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | - | - | - | (10818) | (10818) |
| Balance at September 30, 2020 | 100000000 | $10000 | $250000 | $(560827) | $(300827) |

---

The accompanying notes to financial statements are an integral part of these statements.

---

| |
|:---|
| 6 |
| *[**Table of Contents**](#TOC)* |

---

**LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC. AND SUBSIDIARY**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(UNAUDITED)**

**NOTE 1. NATURE OF OPERATIONS AND SUMMARY OF ACCOUNTING POLICIES**

***Organization***

Lazuriton Nano Biotechnology (U.S.A.) Inc., a company in the developmental stage (the "Company"), was incorporated on June 2, 2015 in the State of Nevada. The Company has conducted limited business operations and had no revenues from operations since its inception. The Company's business plan is to market and distribute Nano fertilizers products.

On March 9, 2020, Lazuriton Co., Ltd, a wholly-owned subsidiary was established in the Republic of China, Taiwan. The subsidiary was established for business operations in Taiwan. In May 2021, the subsidiary was terminated by the local government due to inactivity.

***Going Concern***

These consolidated financial statements were prepared on the basis of accounting principles applicable to going concern, which assumes the realization of assets and discharge of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company had incurred net loss of $30,850 and $32,291 for the nine months ended September 30, 2021 and 2020, respectively, and had accumulated deficit of $610,627 and $579,777 as of September 30, 2021 and December 31, 2020, respectively, and it had no revenue from operations.

The Company faces all the risks common to companies at development stage, including capitalization and uncertainty of funding sources, high initial expenditure levels, uncertain revenue streams, and difficulties in managing growth. The Company's losses raise substantial doubt about its ability to continue as a going concern. The Company's financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.

The Company is currently addressing its liquidity issue by continually seeking additional funds through private placements of its securities and/or capital contributions and loans by Chih-Yuan Hsiao, the President and a member of the board of directors. The Company believes its current and future plans enable it to continue as a going concern. The Company's ability to achieve these objectives cannot be determined at this time, however. If the Company is unable to obtain additional financing, it may be required to reduce the scope of our business development activities, which could harm its business plans, financial condition and operating results. Additional funding may not be available on favorable terms, if at all. These consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts which may differ from those in the accompanying consolidated financial statements.

***Principle of Consolidation***

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant inter-company accounts and transactions have been eliminated in consolidation.

***Use of Estimates***

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the amount of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. However, actual results could differ materially from those results.

---

| |
|:---|
| 7 |
| *[**Table of Contents**](#TOC)* |

---

***Classification***

Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.

***Cash and Cash Equivalents***

Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.

***Net Loss Per Share***

Basic income (loss) per share is computed by dividing net income (loss) by weighted average number of shares of common stock outstanding during each period. Diluted income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. At September 30, 2021 and December 31, 2020, the Company did not have any outstanding common stock equivalents; therefore, a separate computation of diluted loss per share is not presented.

***Income Taxes***

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. The deferred income tax assets were $0 as of both September 30, 2021 and December 31, 2020, respectively.

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires that the Company recognizes deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities by using enacted tax rates expected to apply to taxable income in the periods in which the deferred tax liability or asset is expected to be settled or realized. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized.

***Foreign Currency Translation and Transactions***

The reporting and functional currency of the Company is the USD. The functional currency of Lazuriton Co., Ltd, a wholly owned subsidiary of the Company, is the New Taiwanese Dollar ("TWD").

For financial reporting purposes, the financial statements of the Company's Taiwan subsidiary, which are prepared using the TWD, are translated into the Company's reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. Stockholders' equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive income in stockholders' deficit.

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction gain (loss), is included in the accompanying condensed consolidated statements of operations.

---

| |
|:---|
| 8 |
| *[**Table of Contents**](#TOC)* |

---

***Recent Accounting Pronouncements***

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact that the standard will have on its financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) ("ASU 2020-04"). ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company continues to evaluate the impact of the guidance and may apply the elections as applicable as changes in the market occur.

**NOTE 2. ACCRUED EXPENSES**

Accrued expenses consist of the following:

---

| | | |
|:---|:---|:---|
|  | **September 30, 2021** | **December 31, 2020** |
| Accrued professional fees | $97329 | $73829 |
| Accrued edgar agent service fees | 868 | 868 |
| Accrued transfer agent fees | 4350 | 3000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $102547 | $77697 |

---

**NOTE 3. DUE TO RELATED PARTIES**

The Company has received advances from its officers and shareholders for working capital purposes. As of September 30, 2021 and December 31, 2020, there were $249,428 and $243,428 advances outstanding, respectively. The Company has agreed that the outstanding balances bear 0% interest rate and are due upon demand after 30 days written notice by the officer and shareholder.

**NOTE 4. INCOME TAXES**

*United States of America*

The Company is incorporated in the United States of America and is subject to United States federal taxation. No provisions for income taxes have been made as the Company has no taxable income for the period. The applicable income tax rate for the Company was 21% for the nine months ended September 30, 2021 and 2020.

As of September 30, 2021, the Company had net operating loss carryforwards of approximately $610,627 that may be available to reduce future years' taxable income. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards.

*Taiwan*

The Company's subsidiary is incorporated in Taiwan. The Taiwan Income Tax Law imposes a unified enterprise income tax rate of 20% on all enterprises with taxable income greater than approximately $4,274 (NT$120,000). No income tax liabilities existed as of September 30, 2021 due to its inactivity.

---

| |
|:---|
| 9 |
| *[**Table of Contents**](#TOC)* |

---

The provision for federal income tax consists of the following for the nine months ended September 30, 2021 and 2020, respectively:

---

| | | |
|:---|:---|:---|
|  | **For the Nine Months Ended**<br>**September 30,** | **For the Nine Months Ended**<br>**September 30,** |
|  | **2021** | **2020** |
| Federal income tax benefit attributable to: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current Operations | $6479 | $6781 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: valuation allowance | (6479) | (6781) |
| Net provision for Federal income taxes | $- | $- |

---

The tax effects of temporary differences and carryforwards that give rise to significant portions of deferred tax assets and liabilities consist of the following as of September 30, 2021 and December 31, 2020, respectively:

---

| | | |
|:---|:---|:---|
|  | **September 30, 2021** | **December 31, 2020** |
| Deferred tax asset attributable to: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net operating loss carryover | $128232 | $121753 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: valuation allowance | (128232) | (121753) |
| Net deferred tax asset | $- | $- |

---

The differences between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:

---

| | | |
|:---|:---|:---|
|  | **For the Nine Months Ended**<br>**September 30,** | **For the Nine Months Ended**<br>**September 30,** |
|  | **2021** | **2020** |
| U.S. statutory federal tax benefit | (21)% | (21)% |
| Change in deferred tax asset valuation allowance | 21% | 21% |
| Taiwan statutory tax benefit | (20)% | (20)% |
| Change in deferred tax asset valuation allowance | 20% | 20% |
| Provision for income taxes | -% | -% |

---

For the nine months ended September 30, 2021 and 2020, the Company had no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

**NOTE 5. SUBSEQUENT EVENT**

Management has evaluated subsequent events through the date which the financial statements are available to be issued. All subsequent events requiring recognition as of September 30, 2021 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, "Subsequent Events."

---

| |
|:---|
| 10 |
| *[**Table of Contents**](#TOC)* |

---

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operation.**

***Cautionary Note Regarding Forward-Looking Statements***

This Quarterly Report on Form 10-Q, including this discussion and analysis by management, contains or incorporates forward-looking statements. All statements other than statements of historical fact made in report are forward looking. In particular, the statements herein regarding industry prospects and future results of operations or financial position are forward-looking statements. These forward-looking statements can be identified by the use of words such as "believes," "estimates," "could," "possibly," "probably," anticipates," "projects," "expects," "may," "will," or "should" or other variations or similar words. No assurances can be given that the future results anticipated by the forward-looking statements will be achieved. Forward-looking statements reflect management's current expectations and are inherently uncertain. Our actual results may differ significantly from management's expectations.

The following discussion and analysis should be read in conjunction with our financial statements, included herewith. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future. Such discussion represents only the best present assessment of our management.

**Going Concern**

We have indicated on our financial statements for the nine months ended September 30, 2021 that conditions exist that raise substantial doubt about our ability to continue as a going concern due to our recurring losses from operations, deficit in equity, and the need to raise additional capital to fund operations. A "going concern" opinion could impair our ability to finance our operations through the sale of debt or equity securities.

We require additional funding to meet its ongoing obligations and to fund anticipated operating losses. Our auditor has expressed substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent on raising capital to fund its initial business plan and ultimately to attain profitable operations. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset, or the amounts and classification of liabilities that might result from this uncertainty.

We expect to incur marketing and professional and administrative expenses as well expenses associated with maintaining our filings with Securities and Exchange Commission. We will require additional funds during this time and will seek to raise the necessary additional capital. If we are unable to obtain additional financing, we may be required to reduce the scope of our business development activities, which could harm our business plans, financial condition, and operating results. Additional funding may not be available on favorable terms, if at all. We intend to continue to fund its business by way of equity or debt financing and advances from related parties. Any inability to raise capital as needed would have a material adverse effect on our business, financial condition, and results of operations.

If we cannot raise additional funds, we will have to cease business operations. As a result, our common stock investors would lose all of their investment.

**Results of Operations**

***Three months ended September 30, 2021 compared to the three months ended September 30, 2020***

*Net revenue*: We did not generate any revenue for the three months ended September 30, 2021 and 2020. We have had limited business operations since incorporation.

*General and administrative expenses*: General and administrative expenses primarily consist of legal and professional service fees. General and administrative expenses were $9,950 for the three months ended September 30, 2021, as compared to $10,818 for the three months ended September 30, 2020, which represented a decrease of $868, or 8%. The decrease in general and administrative expenses was insignificant.

---

| |
|:---|
| 11 |
| *[**Table of Contents**](#TOC)* |

---

*Net loss*: Our net loss was $9,950 for the three months ended September 30, 2021, as compared to $10,818 for the three months ended September 30, 2020, which represented a decrease of $868, or 8%. The decrease in net loss was a result of the decrease in general and administrative expenses.

**Results of Operations**

***Nine months ended September 30, 2021 compared to the nine months ended September 30, 2020***

*Net revenue*: We did not generate any revenue for the nine months ended September 30, 2021 and 2020. We have had limited business operations since incorporation.

*General and administrative expenses*: General and administrative expenses primarily consist of legal and professional service fees. General and administrative expenses were $30,850 for the nine months ended September 30, 2021, as compared to $32,292 for the nine months ended September 30, 2020, which represented a decrease of $1,442, or 4%. Such decrease in general and administrative expenses was due to the decrease in professional expenses.

*Net loss*: Our net loss was $30,850 for the nine months ended September 30, 2021, as compared to $32,291 for the nine months ended September 30, 2020, which represented a decrease of $1,441, or 4%. Such decrease in net loss was a result of the decrease in general and administrative expenses.

**Liquidity and Capital Resources**

Cash and cash equivalents were $1,348 at September 30, 2021 and $1,348 at December 31, 2020. Our total current assets were $1,348 at September 30, 2021, as compared to $1,348 at December 31, 2020. Our total current liabilities were $351,975 at September 30, 2021, as compared to $321,125 at December 31, 2020.

We had negative working capital of $350,627 at September 30, 2021, compared to negative working capital of $319,777 at December 31, 2020. The increase in negative working capital was primarily due to the increase in accrued expenses.

Net cash from operating activities was $0 for nine months ended September 30, 2021 and $1 provided by operating activities for the nine months ended September 30, 2020. The net losses from both periods were offset with changes in assets and liabilities.

We had no net cash flow from investing or financing activities during the nine months ended September 30, 2021 and 2020.

We had no net change in cash and cash equivalent for the nine months ended September 30, 2021 and 2020.

**Critical Accounting Policies**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities in the financial statements and accompanying notes. The SEC has defined a company's critical accounting policies as the ones that are most important to the portrayal of the company's financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have not identified any additional critical accounting policies and judgments. We also have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are described in the Note 1 to our financial statements. Although we believe that our estimates, assumptions and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments or conditions.

---

| |
|:---|
| 12 |
| *[**Table of Contents**](#TOC)* |

---

**Off-balance Sheet Arrangements**

We were not aware of any off-balance sheet arrangements as of September 30, 2021.

**Recent Accounting Pronouncements**

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

**Inflation**

Our opinion is that inflation has not had a material effect on our operations and is not expected to have any material effect on our operations.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk.**

As a smaller reporting company, we are not required to provide this information.

**Item 4. Controls and Procedures.**

**Disclosure Controls and Procedures**

We maintain disclosure controls and procedures designed to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that the information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. We performed an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on their evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were not effective as of September 30, 2021.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures is also based partially on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

**Changes in Internal Control Over Financial Reporting**

There were no changes in our internal controls over financial reporting that occurred during our last fiscal quarter to which this Quarterly Report on Form 10-Q relates that have materially affected, or are reasonably likely to materially affect our internal controls over financial reporting.

---

| |
|:---|
| 13 |
| *[**Table of Contents**](#TOC)* |

---

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings.**

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

**Item 1A. Risk Factors.**

As a smaller reporting company, we are not required to provide this information.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

None in the quarter ended September 30, 2021.

**Item 3. Defaults upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures**.

Not applicable.

**Item 5. Other Information.**

None.

---

| |
|:---|
| 14 |
| *[**Table of Contents**](#TOC)* |

---

**Item 6. Exhibits.**

The following exhibits are filed as part of this quarterly report, pursuant to Item 601 of Regulation S-K. All exhibits are attached hereto unless otherwise noted.

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| [31.1 \*](lznn_ex311.htm) | [Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](lznn_ex311.htm) |
| [31.2 \*](lznn_ex312.htm) | [Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](lznn_ex312.htm) |
| [32.1 \*\*](lznn_ex321.htm) | [Certification of the Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 906 of the Sarbanes-Oxey Act of 2002](lznn_ex321.htm) |
| [32.2 \*\*](lznn_ex322.htm) | [Certification of the Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 906 of the Sarbanes-Oxey Act of 2002](lznn_ex322.htm) |

---

____________

\* Filed herewith

\*\* The certifications attached as Exhibits 32.1 and 32.2 accompany this quarterly report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed "filed" by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

---

| |
|:---|
| 15 |
| *[**Table of Contents**](#TOC)* |

---

**SIGNATURES**

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Lazuriton Nano Biotechnology (U.S.A.) Inc.** | **Lazuriton Nano Biotechnology (U.S.A.) Inc.** |
| Date: March 27, 2023 | By: | */s/ Chih-Yuan Hsiao* |
|  |  | Chih-Yuan Hsiao |
|  |  | Chief and Principal Executive Officer |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE**

**SARBANES-OXLEY ACT OF 2002**

I, Chih-Yuan Hsiao, certify that:

---

| | | |
|:---|:---|:---|
| 1. | I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 of Lazuriton Nano Biotechnology (U.S.A.) Inc.; | I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 of Lazuriton Nano Biotechnology (U.S.A.) Inc.; |
| 2 | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3 | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4 | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|  | a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|  | b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|  | c. | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|  | d. | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
| 5 | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors: | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors: |
|  | a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|  | b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |

---

---

| | | |
|:---|:---|:---|
| Date: March 27, 2023 | By: | */s/ Chih-Yuan Hsiao* |
|  |  | Chih-Yuan Hsiao |
|  |  | Chief and Principal Executive Officer  |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE**

**SARBANES-OXLEY ACT OF 2002**

I, Shieh-Tzu Lee, certify that:

---

| | | |
|:---|:---|:---|
| 1. | I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 of Lazuriton Nano Biotechnology (U.S.A.) Inc.; | I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 of Lazuriton Nano Biotechnology (U.S.A.) Inc.; |
| 2 | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3 | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4 | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|  | a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|  | b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|  | c. | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|  | d. | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
| 5 | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors: | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors: |
|  | a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|  | b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |

---

---

| | | |
|:---|:---|:---|
| Date: March 27, 2023 | By: | */s/ Shieh-Tzu Lee* |
|  |  | Shieh-Tzu Lee |
|  |  | Chief and Principal Financial Officer |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO**

**SECTION 906 OF SARBANES-OXLEY ACT OF 2002**

I, Chih-Yuan Hsiao, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

1. The Quarterly Report on Form 10-Q of Lazuriton Nano Biotechnology (U.S.A.) Inc. (the "Company") for the quarterly period ended September 30, 2021 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (U.S.C. 78m or 78o(d)); and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: March 27, 2023 | By: | */s/ Chih-Yuan Hsiao* |
|  |  | Chih-Yuan Hsiao |
|  |  | Chief and Principal Executive Officer |

---

The foregoing certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of a separate disclosure document.

## Exhibit 32.2

**EXHIBIT 32.2**

**CERTIFICATION PURSUANT TO**

**SECTION 906 OF SARBANES-OXLEY ACT OF 2002**

I, Shieh-Tzu Lee, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

1. The Quarterly Report on Form 10-Q of Lazuriton Nano Biotechnology (U.S.A.) Inc. (the "Company") for the quarterly period ended September 30, 2021 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (U.S.C. 78m or 78o(d)); and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: March 27, 2023 | By: | */s/ Shieh-Tzu Lee* |
|  |  | Shieh-Tzu Lee |
|  |  | Chief and Principal Financial Officer |

---

The foregoing certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of a separate disclosure document.